skip to content

Press Releases

Emmaus Medical’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Status from European Medicines Agency May 29, 2012

Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).

Read More